Authors
Marije Slingerland, Claudia Cerella, Henk-Jan Guchelaar, Marc Diederich, Hans Gelderblom
Publication date
2013/8
Source
Investigational new drugs
Volume
31
Pages
1087-1094
Publisher
Springer US
Description
Cardiac glycosides have a long history in the treatment of cardiac disease. However, several preclinical studies as well as two phase I studies have shown that cardenolides may also possess anticancer effects. The mechanisms of these anticancer effects may include intracellular decrease of K+ and increase of Na+ and Ca2+; intracellular acidification; inhibition of IL-8 production and of the TNF-α/NF-κB pathway; inhibition of DNA topoisomerase II and activation of the Src kinase pathway. To date three cardiac glycosides have been developed for treatment of cancer and were tested in a phase 1 clinical trial to determine dose limiting toxicities and maximum tolerated dose. Future studies of this novel class of anticancer drugs are warranted to determine their possible role in cancer treatment.
Total citations
201420152016201720182019202020212022202320241218152418172017647
Scholar articles
M Slingerland, C Cerella, HJ Guchelaar, M Diederich… - Investigational new drugs, 2013